Iguratimod in Kidney Transplant Recipients
An Open-label Study to Evaluate the Effect of Iguratimod Concomitant With Conventional Immunosuppressive Drugs on Preventing Antibody-induced Rejection in Human Leukocyte Antigen(HLA) Highly Mismatched Kidney Transplant Recipients
Sponsor: The First Affiliated Hospital with Nanjing Medical University
This NA trial investigates Kidney Transplantation and is currently ongoing. The First Affiliated Hospital with Nanjing Medical University leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Sep 2018 — Sep 2020 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital with Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .